{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:28:36Z","timestamp":1788870516039,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T00:00:00Z","timestamp":1422316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>\n                    The safety of a proprietary formulation of buprenorphine hydrochloride administered subcutaneously (\n                    <jats:styled-content style=\"fixed-case\">SC<\/jats:styled-content>\n                    ) to young cats was investigated in a blinded, randomized study. Four cohorts of eight cats aged approximately 4\u00a0months were administered saline, 0.24, 0.72 or 1.20\u00a0mg\/kg\/day buprenorphine\n                    <jats:styled-content style=\"fixed-case\">SC<\/jats:styled-content>\n                    for nine consecutive days, representing 0\u00d7, 1\u00d7, 3\u00d7 and 5\u00d7 of the intended dose. Cats were monitored daily for evidence of clinical reactions, food and water intake and adverse events (\n                    <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                    s). Physical examinations, clinical pathology, vital signs and electrocardiograms (\n                    <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content>\n                    s) were evaluated at protocol\u2010specified time points. Complete necropsy and histopathologic examinations were performed following humane euthanasia. Four buprenorphine\u2010treated cats experienced\n                    <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                    s during the study, two unrelated and two related to study drug administration. The two cats with\n                    <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                    s considered related to drug administration had clinical signs of hyperactivity, difficulty in handling, disorientation, agitation and dilated pupils in one 0.24\u00a0mg\/kg\/day cat and one 0.72\u00a0mg\/kg\/day cat. All of these clinical signs were observed simultaneously. There were no drug\u2010related effects on survival, injection response, injection site inspections, body weight, food or water consumption, bleeding time, urinalysis, respiration rate, heart rate,\n                    <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content>\n                    s, blood pressures, body temperatures, macroscopic examinations or organ weights. Once daily buprenorphine s.c. injections at doses of 0.24, 0.72 and 1.20\u00a0mg\/kg\/day for 9\u00a0consecutive days were well tolerated in young domestic cats.\n                  <\/jats:p>","DOI":"10.1111\/jvp.12203","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T01:14:46Z","timestamp":1422321286000},"page":"434-442","source":"Crossref","is-referenced-by-count":22,"title":["The safety of high\u2010dose buprenorphine administered subcutaneously in cats"],"prefix":"10.1111","volume":"38","author":[{"given":"M. K.","family":"Sramek","sequence":"first","affiliation":[{"name":"Abbott Laboratories Abbott Park IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Haas","sequence":"additional","affiliation":[{"name":"WIL Research Ashland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. D.","family":"Coleman","sequence":"additional","affiliation":[{"name":"WIL Research Ashland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Atterson","sequence":"additional","affiliation":[{"name":"WIL Research Ashland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Hamlin","sequence":"additional","affiliation":[{"name":"QTest Labs LLC Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/01652176.2001.9695109"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.72.4.461"},{"key":"e_1_2_7_4_1","first-page":"3","article-title":"Buprenorphine: new pharmacological aspects","volume":"133","author":"Cowan A.","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1977.tb07533.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.228.1.65"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.5326\/0380507"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1989.tb01541.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2010.00541.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2008.00688.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197917020-00001"},{"key":"e_1_2_7_12_1","first-page":"650","article-title":"Postoperative urinary retention in a dog following morphine with bupivacaine epidural analgesia","volume":"39","author":"Herperger L.J.","year":"1998","journal-title":"Canadian Veterinary Journal"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.68.7.699"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.58.3.0002"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0442.2005.00710.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2005.00275.x"},{"key":"e_1_2_7_17_1","first-page":"70","volume-title":"Saunders Handbook of Veterinary Drugs","author":"Papich M.","year":"2007"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-5616(08)70005-6"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X12444743"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2009.00508.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2003.10.002"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.153.15.462"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2005.00677.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.143.7.185"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-2987.2001.00062.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X13476033"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.164.12.359"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800700211"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2009.09.004"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2002.221.666"},{"key":"e_1_2_7_31_1","unstructured":"United States FDA. (2001)Guidance for Industry 85 Good Clinical\u00a0Practice.http:\/\/www.fda.gov\/downloads\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/ucm052417.pdf. Accessed 4 September 2014."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.243.6.844"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvp.12203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:56:39Z","timestamp":1696236999000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/jvp.12203"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12203","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,27]]}}}